Uterine Sarcoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Podcasts
• Clinical Trials

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions:   Stage I Uterine Sarcoma;   Uterine LeiomyosarcomaInterventions:   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim;   Other: clinical observationSponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)Recruiting - verified November 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions:   Stage I Uterine Sarcoma;   Uterine LeiomyosarcomaInterventions:   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim;   Other: clinical observationSponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)Recruiting - verified March 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions:   Stage I Uterine Sarcoma;   Uterine LeiomyosarcomaInterventions:   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim;   Other: clinical observationSponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)Recruiting - verified November 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions:   Stage I Uterine Sarcoma;   Uterine LeiomyosarcomaInterventions:   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim;   Other: clinical observationSponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)Recruiting - verified February 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions:   Stage I Uterine Sarcoma;   Uterine LeiomyosarcomaInterventions:   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim;   Other: clinical observationSponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)Recruiting - verified November 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions:   Stage I Uterine Sarcoma;   Uterine LeiomyosarcomaInterventions:   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim;   Other: clinical observationSponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)Recruiting - verified August 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions:   Stage I Uterine Sarcoma;   Uterine LeiomyosarcomaInterventions:   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim;   Other: clinical observationSponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)Recruiting - verified March 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions:   Stage I Uterine Sarcoma;   Uterine LeiomyosarcomaInterventions:   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim;   Other: clinical observationSponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)Recruiting - verified November 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions:   Stage I Uterine Sarcoma;   Uterine LeiomyosarcomaInterventions:   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim;   Other: clinical observationSponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)Recruiting - verified August 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions:   Stage I Uterine Sarcoma;   Uterine LeiomyosarcomaInterventions:   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim;   Other: clinical observationSponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)Recruiting - verified November 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials